# Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II):  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/use-of-serological-tests-to-reduce-the-risk-of-transfusion-transmitted-human-t-lymphotropic-virus-types-i-and-ii-htlv-iii-guidance-for-industry/e8ad35aa-47eb-47df-bcd6-5f95ecae4ee9

> FDA guidance document: Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II):  Guidance for Industry. Issue date: February 05, 2020. Get complete insights and analysis.

---

## Details

- Title: Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II):  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Biologics Evaluation and Research
- Office URL: /offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
- Issue Date: 2020-02-05
- Last Changed: 2020-02-06
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-3324">FDA-2018-D-3324</a>

## Related Documents

- [Considerations for the Development of Dried Plasma Products Intended for Transfusion:   Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-development-of-dried-plasma-products-intended-for-transfusion-guidance-for-industry/c0c693ab-7392-4bad-b4c9-de122a24ced4)
- [Human Gene Therapy for Rare Diseases:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-rare-diseases-guidance-for-industry/1cebc8e2-7d3b-4c5f-a4c4-78d1fc112099)
- [Human Gene Therapy for Hemophilia:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-hemophilia-guidance-for-industry/bceafce9-c9f0-4137-9ca5-071464212a06)